Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer

Thomas J. Herzog; Sandro Pignata; Sharad A. Ghamande; Maria-Jesús Rubio; Keiichi Fujiwara; Christof Vulsteke; Deborah K. Armstrong; Jalid Sehouli; Robert L. Coleman; Hani Gabra; Giovanni Scambia; Bradley J. Monk; José A. Arranz; Kimio Ushijima; Rabbie Hanna; Claudio Zamagni; Robert M. Wenham; Antionio González-Martín; Brian Slomovitz; Yan Jia; Lisa Ramsay; Krishnansu S. Tewari; Susan C. Weil; Ignace B. Vergote

doi:10.1016/j.ygyno.2023.01.003

Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer

Thomas J. Herzog
, Sandro Pignata
, Sharad A. Ghamande
, Maria-Jesús Rubio
, Keiichi Fujiwara
, Christof Vulsteke
, Deborah K. Armstrong
, Jalid Sehouli
, Robert L. Coleman
, Hani Gabra
, Giovanni Scambia
, Bradley J. Monk
, José A. Arranz
, Kimio Ushijima
, Rabbie Hanna
, Claudio Zamagni
, Robert M. Wenham
, Antionio González-Martín
, Brian Slomovitz
, Yan Jia

Lisa Ramsay, Krishnansu S. Tewari, Susan C. Weil, Ignace B. Vergote

Risultato della ricerca: Contributo in rivista › Articolo

Lingua originale	Inglese
pagine (da-a)	300-308
Numero di pagine	9
Rivista	Gynecologic Oncology
DOI	https://doi.org/10.1016/j.ygyno.2023.01.003
Stato di pubblicazione	Pubblicato - 2023

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

Keywords

Farletuzumab
Folate receptor-α
MORAb-003
Ovarian cancer
Progression-free survival

Accesso al documento

10.1016/j.ygyno.2023.01.003

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Herzog, T. J., Pignata, S., Ghamande, S. A., Rubio, M.-J., Fujiwara, K., Vulsteke, C., Armstrong, D. K., Sehouli, J., Coleman, R. L., Gabra, H., Scambia, G., Monk, B. J., Arranz, J. A., Ushijima, K., Hanna, R., Zamagni, C., Wenham, R. M., González-Martín, A., Slomovitz, B., ... Vergote, I. B. (2023). Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer. Gynecologic Oncology, 300-308. https://doi.org/10.1016/j.ygyno.2023.01.003

@article{fdc44451785242bea44e9ed1ff148627,

title = "Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer",

keywords = "Farletuzumab, Folate receptor-α, MORAb-003, Ovarian cancer, Progression-free survival, Farletuzumab, Folate receptor-α, MORAb-003, Ovarian cancer, Progression-free survival",

author = "Herzog, \{Thomas J.\} and Sandro Pignata and Ghamande, \{Sharad A.\} and Maria-Jes{\'u}s Rubio and Keiichi Fujiwara and Christof Vulsteke and Armstrong, \{Deborah K.\} and Jalid Sehouli and Coleman, \{Robert L.\} and Hani Gabra and Giovanni Scambia and Monk, \{Bradley J.\} and Arranz, \{Jos{\'e} A.\} and Kimio Ushijima and Rabbie Hanna and Claudio Zamagni and Wenham, \{Robert M.\} and Antionio Gonz{\'a}lez-Mart{\'i}n and Brian Slomovitz and Yan Jia and Lisa Ramsay and Tewari, \{Krishnansu S.\} and Weil, \{Susan C.\} and Vergote, \{Ignace B.\}",

year = "2023",

doi = "10.1016/j.ygyno.2023.01.003",

language = "English",

pages = "300--308",

journal = "Gynecologic Oncology",

issn = "1095-6859",

publisher = "Academic Press Inc.",

}

Herzog, TJ, Pignata, S, Ghamande, SA, Rubio, M-J, Fujiwara, K, Vulsteke, C, Armstrong, DK, Sehouli, J, Coleman, RL, Gabra, H, Scambia, G, Monk, BJ, Arranz, JA, Ushijima, K, Hanna, R, Zamagni, C, Wenham, RM, González-Martín, A, Slomovitz, B, Jia, Y, Ramsay, L, Tewari, KS, Weil, SC & Vergote, IB 2023, 'Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer', Gynecologic Oncology, pagg. 300-308. https://doi.org/10.1016/j.ygyno.2023.01.003

TY - JOUR

T1 - Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer

AU - Herzog, Thomas J.

AU - Pignata, Sandro

AU - Ghamande, Sharad A.

AU - Rubio, Maria-Jesús

AU - Fujiwara, Keiichi

AU - Vulsteke, Christof

AU - Armstrong, Deborah K.

AU - Sehouli, Jalid

AU - Coleman, Robert L.

AU - Gabra, Hani

AU - Scambia, Giovanni

AU - Monk, Bradley J.

AU - Arranz, José A.

AU - Ushijima, Kimio

AU - Hanna, Rabbie

AU - Zamagni, Claudio

AU - Wenham, Robert M.

AU - González-Martín, Antionio

AU - Slomovitz, Brian

AU - Jia, Yan

AU - Ramsay, Lisa

AU - Tewari, Krishnansu S.

AU - Weil, Susan C.

AU - Vergote, Ignace B.

PY - 2023

Y1 - 2023

KW - Farletuzumab

KW - Folate receptor-α

KW - MORAb-003

KW - Ovarian cancer

KW - Progression-free survival

KW - Farletuzumab

KW - Folate receptor-α

KW - MORAb-003

KW - Ovarian cancer

KW - Progression-free survival

UR - http://hdl.handle.net/10807/230638

U2 - 10.1016/j.ygyno.2023.01.003

DO - 10.1016/j.ygyno.2023.01.003

M3 - Article

SN - 1095-6859

SP - 300

EP - 308

JO - Gynecologic Oncology

JF - Gynecologic Oncology

ER -